FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. What is presented is a genetically engineered antibody able to bind human CD138. There are described its heavy and light chain sequences, as well as their CDR.
EFFECT: presented antibody can be used as an ingredient of a pharmaceutical composition for treating tumours.
13 cl, 21 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IMPROVING TARGETED ACTION OF CD138 EXPRESSING TUMOUR CELLS AND AGENTS TO THIS EFFECT | 2008 |
|
RU2486203C2 |
| ANTI-CD138 IMMUNOCONJUGATES AND USING THEM | 2008 |
|
RU2547939C2 |
| APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET | 2010 |
|
RU2561041C2 |
| APPLICATIONS OF IMMUNOCONJUGATES, THE TARGET OF WHICH IS CD138 | 2012 |
|
RU2632108C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| CD37 BINDING MOLECULES AND IMMUNOCONJUGATES | 2011 |
|
RU2610662C9 |
| ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | 2014 |
|
RU2696579C2 |
| ANTI-FOLR1 IMMUNOCONJUGATE APPLICATION SCHEMES | 2014 |
|
RU2801307C1 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
